University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Bigmingham, UK.
Emmeline Centre for Hearing Implants, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
J Int Adv Otol. 2020 Dec;16(3):443-455. doi: 10.5152/iao.2020.9037.
This study aimed to establish outcomes following cochlear implantation (CI) in patients with superficial siderosis (SS). MEDLINE, Embase, Web of Science, Cochrane, and ClinicalTrials.gov databases were searched for this systematic review. No limits were placed on the language or the year of publication. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Of a total of 46 studies, 19 studies met the inclusion criteria reporting outcomes in 38 patients. Of the 44 implants, 23 implants (52.27%) had good hearing outcomes at the last follow-up, 9 (20.45%) were initially beneficial for the patient, but then the performance deteriorated (4 of which were re-implanted), and 12 (27.27%) were not beneficial for the patient. All studies were classified as grade 4 studies using the Oxford Centre for Evidence-Based Medicine (OCEBM) grading system, being retrospective in nature and consisting of case reports and noncontrolled case series with a small number of patients. Of the 44 implants, 32 (72.73%) showed improved hearing outcomes following CI for SS at some point in time, of which 23 (52.2%) implants showed sustained benefit at the last follow-up (average follow-up time was 21.97 months). It is difficult to predict the longevity of benefit owing to the progressive nature of the disease or the patients in whom it may be beneficial, as the preoperative investigations inadequately predict benefit. Preimplantation and postimplantation counseling with the patient and their family regarding the potential limited benefit and eventual parallel decline with the neurological disease are crucial, along with thorough clinical investigations.
本研究旨在探讨耳蜗植入(CI)治疗表浅性铁质沉着症(SS)患者的结局。本系统评价检索了 MEDLINE、Embase、Web of Science、Cochrane 和 ClinicalTrials.gov 数据库。未对语言或发表年份设限。该综述的开展符合系统评价和荟萃分析的首选报告项目(PRISMA)声明。在总共 46 项研究中,有 19 项研究符合纳入标准,共纳入 38 例患者,报告了结局。在 44 个植入物中,23 个(52.27%)在最后一次随访时听力结局良好,9 个(20.45%)最初对患者有益,但随后性能恶化(其中 4 个进行了再植入),12 个(27.27%)对患者无益。所有研究均使用牛津循证医学中心(OCEBM)分级系统被归类为 4 级研究,均为回顾性研究,由病例报告和非对照病例系列组成,患者数量较少。在 44 个植入物中,32 个(72.73%)在某个时间点因 SS 行 CI 后听力结局得到改善,其中 23 个(52.2%)植入物在最后一次随访时仍保持获益(平均随访时间为 21.97 个月)。由于疾病的进展性质或可能从中获益的患者,获益的持久性难以预测,因为术前检查不能充分预测获益。在术前和术后向患者及其家属提供有关潜在有限获益以及最终与神经疾病平行下降的咨询非常重要,同时还需要进行彻底的临床检查。